New Combination Approach Aids in Increased Cancer Cell Death

Researchers conducted a small study which suggests that adding the antibody complement factor H or CFH to a chemotherapy treatment can have a boosting effect.

In some leukemia patients, adding an investigational antibody to the chemotherapy rituximab can improve the cancer-killing properties, according to a small, proof-of-concept study by Duke Cancer Institute researchers. //

The study, published in the Journal PLOS ONE, tested the new antibody in the blood of 11 patients with chronic lymphocytic leukemia. This lays the groundwork for a phase 1 clinical trial this is slated to begin next year.

Scientists Develop Compound That Triggers Cancer Cell Death
Researchers at the Dana-Farber Cancer Institute have claimed that they have developed a new compound that can make cancer cells to self destruct.

‘Complement factor H or CFH is an antibody that works to protect cells. By adding CFH antibody to rituximab increases the death of cancer cells.’

"This work builds on earlier findings that some patients are naturally resistant to the chemotherapy drug rituximab," said senior author Edward F. Patz, Jr., M.D., the James and Alice Chen Professor of Radiology at Duke.

Patz is also professor in the departments of Pathology and Pharmacology & Cancer Biology. "The drug works in part through an immune mechanism that triggers cancer cells to die. In some people, this immune mechanism is de-activated. Our antibody basically re-activates it."

In earlier studies, Patz and colleagues identified an antibody against a protein called complement factor H, or CFH, which works to protect cells. Patz's team found that people who have the antibody have a natural capacity to fight cancer, since the antibody basically shuts off a cancer cell's security system and makes it more vulnerable to drugs or immune fighters.

Scientists Create New Process to Program Cancer Cell Death
A fundamentally new approach to killing cancer cells has been created by scientists.

One of the drugs this antibody could potentially aid is rituximab, which is used to treat leukemia, but in some patients it only has limited effect. To test that approach, Patz and colleagues first determined whether the 11 leukemia patients were sensitive to rituximab based on an analysis of their leukemic cells in their blood. Ten of the 11 patients were determined to be non-responders when the tumor cells were challenged with rituximab.

But when the investigational CFH antibody was added to rituximab, five of the 11 patients (45 percent) had a significant increase in cancer cell death.

Method Employed by Specific Virus to Kill Cancer Cells
Study conducted by the Scientists has led to the discovery of a mechanism by which specific virus (vesicular stomatitis virus) aids in the death of cancer cells.

"This is a combination approach, and it appears to strip away immune protection of cancer cells," Patz said. "Patients who had been rituximab resistant became rituximab sensitive."

Patz said the antibody was developed in his lab and has been licensed by Duke to Grid Therapeutics; he is a co-founder and has a financial interest in the company. The planned phase 1 clinical trial of the antibody will first target advance solid tumors, including lung, breast and colon cancers.

Neem Tree Extract Shows Promise in Treating Pancreatic Cancer
A natural extract derived from India's neem tree could potentially be used to treat pancreatic cancer.

Source-Eurekalert